INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 47m ago
HOUSE PTR7m ago
SEC 13F7m ago
ROBINHOOD CHAIN7m ago
Public company

Biohaven Ltd.

BHVNCIK 0001935979

EDGAR filingsOpen in network
Price$14.48
1 year+73.6%
Disclosed transactions14
Buys / sells1 / 0
Max Insider Score46
Connections with evidence8

BHVN · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
MK
Mehta KishanDirector
BHVNBiohaven Ltd.
Grant or award
A—
68.7K sh
Apr 28, 2026Apr 30, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    CHECKMATE GOVERNMENT RELATIONSLDA Q1 2026 first quarter · MED, Pharmacy, Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Antonijevic IrinaDirector · Apr 30, 2026
  • ← Insider ofevidence
    Mehta KishanDirector · Mar 19, 2026
  • ← Insider ofevidence
traded Apr 28, 2026
+2d
SEC FORM 4

Evidence

9
AI
Antonijevic IrinaDirector
BHVNBiohaven Ltd.
Grant or award
A—
68.7K sh
Apr 28, 2026Apr 30, 2026
traded Apr 28, 2026
+2dSEC FORM 4

Evidence

12
MK
Mehta KishanDirector
BHVNBiohaven Ltd.
Gift
G—
17.3K sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

12
MK
Mehta KishanDirector
BHVNBiohaven Ltd.
Gift
G—
17.3K sh
Mar 17, 2026Mar 19, 2026
traded Mar 17, 2026
+2dSEC FORM 4

Evidence

9
BM
Buten MatthewChief Financial Officer
BHVNBiohaven Ltd.
Option exercise
M—
4,250 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

21
BM
Buten MatthewChief Financial Officer
BHVNBiohaven Ltd.
Option exercise
M—
4,250 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

17
CB
Car BruceChief Scientific Officer
BHVNBiohaven Ltd.
Tax withholding
F$24K
2,381 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

21
CB
Car BruceChief Scientific Officer
BHVNBiohaven Ltd.
Option exercise
M—
4,750 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

9
BM
Buten MatthewChief Financial Officer
BHVNBiohaven Ltd.
Tax withholding
F$26K
2,594 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

21
CC
Clark George C.VP, Chief Accounting Officer
BHVNBiohaven Ltd.
Option exercise
M—
2,500 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

21
CB
Car BruceChief Scientific Officer
BHVNBiohaven Ltd.
Option exercise
M—
4,750 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

9
CC
Clark George C.VP, Chief Accounting Officer
BHVNBiohaven Ltd.
Option exercise
M—
2,500 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

9
CC
Clark George C.VP, Chief Accounting Officer
BHVNBiohaven Ltd.
Tax withholding
F$11K
1,117 sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

46
BG
Bailey GregoryDirector
BHVNBiohaven Ltd.
Open-market purchase
BUY$3.00M
400.0K sh
Nov 13, 2025Nov 17, 2025
traded Nov 13, 2025
+4dSEC FORM 4

Evidence

Buten Matthew
Chief Financial Officer · Jan 7, 2026
  • ← Insider ofevidence
    Car BruceChief Scientific Officer · Jan 7, 2026
  • ← Insider ofevidence
    Clark George C.VP, Chief Accounting Officer · Jan 7, 2026
  • ← Insider ofevidence
    Bailey GregoryDirector · Nov 17, 2025

    • Lobbying

    $200K reported · de-duplicated
    2026 Q2 $120K via firms2026 Q1 $80K via firms
    • CHECKMATE GOVERNMENT RELATIONS$120K2026 Q2 · posted Aug 26, 2026 · Health issues, MED, Pharmacy
    • CHECKMATE GOVERNMENT RELATIONS—2026 Q1 · posted Aug 26, 2026 · Health issues, MED, Pharmacy
    • CHECKMATE GOVERNMENT RELATIONS$80K2026 Q1 · posted Aug 26, 2026 · MED, Pharmacy, Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.